A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis

Int J Pancreatol. 1997 Feb;21(1):13-9. doi: 10.1007/BF02785915.


Conclusion: In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.

Background: Somatostatin and its long-acting analog octreotide have both been proposed for the treatment of patients with acute pancreatitis, but neither agent has been adequately assessed in patients with severe attacks.

Methods: Fifty-eight patients with moderate or severe acute pancreatitis who were admitted to hospitals within the west of Scotland over an 18-mo period were randomized to receive octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 d, or placebo in addition to standard supportive therapy.

Results: There was no significant difference in the incidence of complications (54% octreotide group and 40% placebo group) or mortality (octreotide group 18%; placebo group 20%).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Octreotide / adverse effects
  • Octreotide / therapeutic use*
  • Pancreatitis / drug therapy*
  • Pancreatitis / mortality


  • Octreotide